GOOD NEWS丨Congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection

On January 08, 2024, NMPA published the drug approval certification document delivery information release shows that Guangzhou Green Cross receives drug approval of dexamethasone palmitate injection, Approval Number: SFDA HB2200446.Warmly congratulations to Guangzhou Green Cross on the approval of Dexamethasone Palmitate Injection.

As a strategic partner of Guangzhou Green Cross, Yeedozencom undertook the BE of this project. Thanks Guangzhou Green Cross for their trust and support!

In recent years, the R&D of corticosteroid anti-inflammatory drugs in China has been unprecedentedly active. Dexamethasone palmitate injection is characterized by targeting, slow-releasing, high efficiency and safety, and its advantages are specifically manifested in ultra-long acting, more efficient anti-inflammatory, safer drug delivery. With more and more explorations on dexamethasone, related R&D and clinical trials are emerging. As a strategic partner of Guangzhou Green Cross, both sides jointly carry out clinical trials on the expansion of indications and further conduct related research and trials

Yeedozencom provides the whole process services from the aspects of trial protocol design, project management, clinical monitoring, quality assurance and summary report. After receiving the ethical approval on April 30, 2021 and starting the project in September of the same year, the last subject out of the group at the end of October, and the submission of application materials was completed on January 13, 2022. Actively cooperate to answer questions about clinical trials raised by verification experts. Finally assisted the client to complete the approval of dexamethasone palmitate injection.

Thanks again for the trust of Guangzhou Green Cross, we will uphold the vision of becoming a first-class value-added service provider for the whole life cycle of pharmaceuticals, and help more companies to promote good drugs to market.